4//SEC Filing
BioLexis Pte Ltd. 4
Accession 0001209191-19-062163
CIK 0001649989other
Filed
Dec 29, 7:00 PM ET
Accepted
Dec 30, 5:14 PM ET
Size
12.5 KB
Accession
0001209191-19-062163
Insider Transaction Report
Form 4
Pillai Arun Kumar
Director10% Owner
Transactions
- Exercise/Conversion
Warrant (Right to Buy)
2019-12-23−3,636,364→ 0 totalExercise: $0.23Exp: 2019-12-24→ Common Stock (3,636,364 underlying) - Exercise/Conversion
Common Stock
2019-12-23$0.23/sh+2,909,091$674,909→ 16,948,585 total
GMS Tenshi Holdings Pte. Ltd
DirectorChief Executive Officer10% Owner
Transactions
- Exercise/Conversion
Common Stock
2019-12-23$0.23/sh+2,909,091$674,909→ 16,948,585 total - Exercise/Conversion
Warrant (Right to Buy)
2019-12-23−3,636,364→ 0 totalExercise: $0.23Exp: 2019-12-24→ Common Stock (3,636,364 underlying)
Sukhtian Ghiath M.
Director10% Owner
Transactions
- Exercise/Conversion
Common Stock
2019-12-23$0.23/sh+2,909,091$674,909→ 16,948,585 total - Exercise/Conversion
Warrant (Right to Buy)
2019-12-23−3,636,364→ 0 totalExercise: $0.23Exp: 2019-12-24→ Common Stock (3,636,364 underlying)
Footnotes (5)
- [F1]Represents the actual number of shares of common stock received upon the net exercise of such warrant in full in accordance with its amended terms.
- [F2]These securities are held of record by BioLexis Pte Ltd. ("BioLexis"). Tenshi Life Sciences Private Limited ("Tenshi"), a private investment vehicle controlled by Arun Kumar Pillai ("Kumar"), and GMS Pharma (Singapore) Pte. Limited ("GMS Pharma"), a private investment company and wholly-owned subsidiary of GMS Holdings, are the 50:50 beneficial owners of BioLexis, in which each of Tenshi and GMS Pharma owns 50% of the outstanding voting shares. Kumar, a natural person, is the holder of a controlling interest in Tenshi. Ghiath M. Sukhtian ("Ghiath Sukhtian"), a natural person, is the holder of a controlling interest in GMS Holdings, which is the holder of a controlling interest in GMS Pharma.
- [F3]By virtue of the relationships described above in Footnote 2, Kumar and Ghiath Sukhtian may be deemed to have voting and investment power with respect to the securities held by BioLexis noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. BioLexis has designated four representatives to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
- [F4]Immediately exercisable.
- [F5]The Warrant was acquired by BioLexis in the Issuer's April 2019 public offering of shares and accompanying warrants at a combined purchase price of $2.75 per share of Common Stock and accompanying 15-month warrants and 5-year warrants. The Warrants originally had an exercise price of $2.90 per share but were amended on 12/23/2019 to reduce the exercise price to $0.232 per share and shorten the expiration date to 12/24/2019.
Documents
Issuer
Outlook Therapeutics, Inc.
CIK 0001649989
Entity typeother
IncorporatedSingapore
Related Parties
1- filerCIK 0001716335
Filing Metadata
- Form type
- 4
- Filed
- Dec 29, 7:00 PM ET
- Accepted
- Dec 30, 5:14 PM ET
- Size
- 12.5 KB